Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 29, 2020
Product Development
COVID-19 Quick Takes: FDA expands remdesivir EUA; plus Warp Speed, Abbott, Moderna-Japan, CanSino-Canada, BeiGene-Singlomics, Sinovac, UNC, Daiichi, Laurent
Remdesivir authorized for mild patientsFDA expanded an emergency use authorization for remdesivir to include all patients hospitalized with COVID-19. The antiviral from Gilead Sciences Inc.
BioCentury | Jun 22, 2020
Emerging Company Profile
Prosit Sole: chimeric proteins for rare disease
Prosit Sole aims to improve known therapeutic proteins, cytokine drugs through chimeras
BioCentury | Oct 4, 2010
Strategy
Times changed
ZymoGenetics, being swallowed by BMS, reminds that business models must adapt
Items per page:
1 - 10 of 37